Canton Strategic Holdings, Inc.
CNTNNasdaq
$2.30
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↑ +41.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$477.7M
Enterprise Value
$477.7M
P/E
—
P/S
—
P/B
1.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$80.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-17.2%
ROIC
-9.2%
Debt / Equity
—
Net Cash
—
Return 1Y
+39.4%
Company profile
Hillstream BioPharma, Inc. develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
- CEO
- Randy D. Milby
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2
- Headquarters
- New Jersey
- Website
- hillstreambio.com
Management & directors
- Appajosyula SireeshChief Executive Officer
- Gravitas Capital LpExecutive Chairman
Roles derived from SEC Form 4 filings.
Earnings
CNTN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.23↓ -76.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.8M | -$3.2M | -$6.9M | -$9.5M | -$12.4M | -$20.1M |
| Net income | -$2.4M | -$2.2M | -$8.5M | -$9.3M | -$12.2M | -$35.9M |
| Diluted EPS | — | — | -$18.72 | -$107.02 | -$9.41 | -$1.12 |
| Operating cash flow | -$1.1M | -$1.1M | -$6.6M | -$7.3M | -$10.9M | -$16.1M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.4M | -$3.9M | -$3.8M | -$2.5M | -$1.9M | -$2.1M | -$13.6M | -$36.9M |
| Net income | -$2.3M | -$3.8M | -$3.8M | -$2.5M | -$1.9M | -$2.1M | -$29.4M | -$47.3M |
| Diluted EPS | -$2.42 | -$2.45 | -$1.99 | -$0.99 | -$0.64 | -$0.34 | $0.85 | -$0.23 |
| Operating cash flow | -$2.2M | -$2.9M | -$3.0M | -$2.7M | -$1.1M | -$1.9M | -$10.4M | -$7.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 14, 2026
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-26 | Stetz Gary S. | Sale | 12,500 | $3.47 | $43,375.00 | filing |
| 2026-05-22 | Stetz Gary S. | Sale | 15,000 | $3.41 | $51,150.00 | filing |
| 2026-05-22 | Stetz Gary S. | Sale | 15,000 | $3.41 | $51,150.00 | filing |
| 2026-05-22 | Stetz Gary S. | Sale | 15,000 | $3.40 | $51,000.00 | filing |
| 2026-05-22 | Stetz Gary S. | Sale | 12,851 | $3.44 | $44,207.44 | filing |
| 2026-05-22 | Stetz Gary S. | Sale | 10,000 | $3.45 | $34,500.00 | filing |
| 2026-05-22 | Stetz Gary S. | Sale | 10,000 | $3.45 | $34,500.00 | filing |
| 2026-05-22 | Stetz Gary S. | Sale | 10,000 | $3.40 | $34,000.00 | filing |
| 2025-06-23 | Anderson Kelly | Award | 6,300 | $0.00 | $0.00 | filing |
| 2025-06-20 | Gravitas Capital LP· Executive Chairman | Buy | 337,838 | $1.48 | $500,000.24 | filing |
| 2025-06-20 | Appajosyula Sireesh· Chief Executive Officer | Buy | 60,806 | $1.48 | $89,992.88 | filing |
| 2025-06-20 | Parikh Sanam | Buy | 1,000 | $1.45 | $1,450.00 | filing |
| 2025-06-20 | Appajosyula Sireesh· Chief Executive Officer | Buy | 690 | $1.42 | $979.80 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.